StageZero Life Sciences Ltd.
SZLSFOTCHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$630018
P/E Ratio—
52W High$0.03109
52W Low$0.0005
StageZero Life Sciences Ltd. (SZLSF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SZLSF · as of 2026-06-15
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.80M | $5.07M | $4.15M | $0.14M | $0.19M |
| Cost of Revenue | $4.20M | $3.89M | $3.46M | $1.10M | $1.27M |
| Gross Profit | ($0.40M) | $1.18M | $0.70M | ($0.96M) | ($1.08M) |
| Gross Margin %(computed) | -10.64% | 23.23% | 16.75% | -692.78% | -580.67% |
| Operating Expenses | |||||
| R&D Expenses | $0.35M | $0.77M | $0.22M | $0.00M | $0.00M |
| G&A Expenses | $5.91M | $6.98M | $4.02M | $4.18M | $3.29M |
| Total Operating Expenses | $7.34M | $9.31M | $4.43M | $4.18M | $3.29M |
| Operating Income | ($7.75M) | ($7.96M) | ($3.74M) | ($5.11M) | ($4.36M) |
| Operating Margin %(computed) | -204.13% | -157.12% | -90.00% | — | — |
| Interest Income | $0.00M | $0.00M | $0.04M | $0.00M | $0.00M |
| Interest Expense | $0.28M | $0.20M | $0.70M | $0.80M | $1.13M |
| Income Before Tax | ($11.42M) | ($7.48M) | ($6.86M) | ($3.48M) | ($3.94M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.83M | $1.14M |
| Net Income | ($11.42M) | ($7.48M) | ($6.86M) | ($3.48M) | ($3.94M) |
| Net Margin %(computed) | -300.79% | -147.67% | -165.32% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.11 | $-0.10 | $-0.15 | $-0.16 | $-0.23 |
| Wtd Avg Shares | 99.43M | 70.72M | 44.82M | 26.50M | 17.11M |
| EBITDA | ($10.27M) | ($5.69M) | ($6.26M) | ($2.44M) | ($2.66M) |
| EBITDA Margin %(computed) | -270.62% | -112.20% | -150.75% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · M
Explore more StageZero Life Sciences Ltd. data
About StageZero Life Sciences Ltd. (SZLSF) Income Statement
StageZero Life Sciences Ltd. (SZLSF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, SZLSF reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -10.64%), and net income of ($0.01B) — a net profit margin of -300.79%.
Frequently asked questions
SZLSF · 4 questionsStageZero Life Sciences Ltd. (SZLSF) reported revenue of $0.00B for 2022, down 25.1% year-over-year.
SZLSF revenueSZLSF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15